Details of interaction between fat type and roasting temperature on the cholesterol oxidation products of beef sausages. by Kazeem Dauda Adeyemi (21181818)

Subjects:

Lipid oxidation and protein oxidation in beef sausage containing different fats and roasted at different temperatures. by Kazeem Dauda Adeyemi (21181818)

Subjects:

Principal component analysis (PCA) of the characteristics of beef sausages containing different fat types and cooked at different temperatures. by Kazeem Dauda Adeyemi (21181818)

Subjects:

Composition of beef sausage. by Kazeem Dauda Adeyemi (21181818)

Subjects:

Percentage distribution (weighted) of surveyed facilities in 2014 and 2017. by Rajon Banik (12066099)

Subjects:

Textural profile of beef sausage containing different fats and roasted at different temperature. by Kazeem Dauda Adeyemi (21181818)

Subjects:

Chemical composition and physicochemical properties of beef sausages containing different fats and roasted at different temperatures. by Kazeem Dauda Adeyemi (21181818)

Subjects:

Active DNA Demethylation Mediated by <i>OsGADD45a2</i> Regulates Growth, Development, and Blast (Magnaporthe oryzea) Resistance in Rice by Ganghua Zhou (9283406)

“…In <i>OsGADD45a2</i> overexpression lines, significant decreases in CG and CHG methylation levels were observed in protein-coding genes, leading to their upregulation. …”

Changes in AL (A) and SE (B) according to the treatment time estimation curve in patients given 0.125% atropine. by Zi-Rong Chen (9227618)

Subjects:

Flow diagram of the patient selection into the final analysis. by Zi-Rong Chen (9227618)

Subjects:

Patients’ demographics and clinical parameters. by Zi-Rong Chen (9227618)

Subjects:

Associations between demographic variables, In4_SED and SE changes at 6 and 12 months after 4_SED (<i><i>n</i></i> = 80). by Zi-Rong Chen (9227618)

Subjects:

Table 2 - Early identification of the efficacy of 0.125% atropine treatment for children with Myopia: A prospective pilot study by Zi-Rong Chen (9227618)

Subjects:

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

Image 1_Chromosome 1 variants associated with decreased HIV set-point viral load correlate with PRKAB2 expression changes.png by Riley H. Tough (14432838)

Supplementary file 1_Biodegradable plastic film mulch increased nitrous oxide emissions in organic leek but decreased emissions in organic cabbages.docx by Martin Samphire (22525445)

Table 1_Beyond interferon gamma - decreased cellular response to COVID-19 vaccination booster in patients with autoimmune inflammatory rheumatic diseases.docx by Jakub Wroński (14031216)